GMMMG logo

NHS photos

NHS logo

High Cost Drugs in Development

 

On this page you will find Blueteq forms that are currently going through the GMMMG approval process. You will be able to comment on draft forms out for consultation via the links in the table below.

Title

Information

Comments

End date

01

Blueteq forms for transition from paediatric (NHSE commissioned) to adult (CCG commissioned) for JIA for  Abatacept, Adalimumab, Anakinra, Etanercept, infliximab, Rituximab and Tocilizumab have been developed for use across GM

On behalf of the GMMMG High Cost Drugs Subgroup, the following Blueteq forms for transition from paediatric (NHSE commissioned) to adult (CCG commissioned) for JIA for

  • Abatacept
  • Adalimumab
  • Anakinra
  • Etanercept
  • infliximab
  • Rituximab
  • Tocilizumab

    [All document links removed- consultation closed]

have been developed for use across GM.

We now seek comments from GM NHS healthcare professionals on the content of these forms. This consultation period is open until 5:00pm on 9th August 2017. Comments will be considered by the GMMMG High Cost Drugs Subgroup prior to a final draft form being approved for use.

The Pharmaceutical Industry is invited to comment on factual inaccuracies only.

Comments Form
[Link removed- consultation closed]

5:00pm
Wednesday
9th August 2017

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer